These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30997535)

  • 1. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
    Holland BC; Sood A; Delfino K; Dynda DI; Ran S; Freed N; Alanee S
    Cancer Immunol Immunother; 2019 Jun; 68(6):991-997. PubMed ID: 30997535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.
    Xylinas E; Robinson BD; Kluth LA; Volkmer BG; Hautmann R; Küfer R; Zerbib M; Kwon E; Thompson RH; Boorjian SA; Shariat SF
    Eur J Surg Oncol; 2014 Jan; 40(1):121-7. PubMed ID: 24140000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
    Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma.
    Faraj SF; Munari E; Guner G; Taube J; Anders R; Hicks J; Meeker A; Schoenberg M; Bivalacqua T; Drake C; Netto GJ
    Urology; 2015 Mar; 85(3):703.e1-6. PubMed ID: 25733301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
    Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
    Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.
    Sjödahl G; Lövgren K; Lauss M; Chebil G; Patschan O; Gudjonsson S; Månsson W; Fernö M; Leandersson K; Lindgren D; Liedberg F; Höglund M
    Urol Oncol; 2014 Aug; 32(6):791-7. PubMed ID: 24794251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
    Gulinac M; Dikov D; Velikova T; Belovezhdov V
    Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
    Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.
    Gordetsky JB; Montgomery KW; Giannico GA; Rais-Bahrami S; Thapa P; Boorjian S; Frank I; Cheville J
    Int J Surg Pathol; 2022 Feb; 30(1):6-14. PubMed ID: 34180731
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
    Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
    Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy.
    Sikic D; Weyerer V; Geppert CI; Bertz S; Lange F; Taubert H; Wach S; Schmitz-Draeger BJ; Wullich B; Hartmann A; Eckstein M
    Urol Oncol; 2022 Feb; 40(2):63.e19-63.e26. PubMed ID: 34420870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal-subtype bladder tumours show a 'hot' immunophenotype.
    Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
    Hwang EC; Sathianathen NJ; Imamura M; Kuntz GM; Risk MC; Dahm P
    Cochrane Database Syst Rev; 2019 May; 5(5):CD013336. PubMed ID: 31111956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.
    Mahmoud AM; Frank I; Orme JJ; Lavoie RR; Thapa P; Costello BA; Cheville JC; Gupta S; Dong H; Lucien F
    BMC Urol; 2022 Jun; 22(1):90. PubMed ID: 35751046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.